Telatinib for Carcinoma, Hepatocellular

Phase-Based Estimates
1
Effectiveness
2
Safety
The Angeles Clinic and Research Institute, Los Angeles, CA
Carcinoma, Hepatocellular+3 More
Telatinib - Drug
Eligibility
18+
All Sexes
Eligible conditions
Carcinoma, Hepatocellular

Study Summary

This study is evaluating whether a drug may help treat stomach and liver cancer.

See full description

Eligible Conditions

  • Carcinoma, Hepatocellular
  • Carcinoma
  • Hepatocellular Carcinoma
  • Malignant Neoplasm of Stomach

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether Telatinib will improve 1 primary outcome and 4 secondary outcomes in patients with Carcinoma, Hepatocellular. Measurement will happen over the course of from the start of treatment until 30 days following the end of treatment or until initiation of a new anticancer therapy (whichever occurs first), approximately 13 months.

Month 13
Incidence and severity of adverse events
Year 10
Progression-free survival
Month 18
Overall survival
Month 12
Disease control rate
Overall response rate

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Compared to trials

Trial Design

2 Treatment Groups

Control
telatinib + Keytruda

This trial requires 45 total participants across 2 different treatment groups

This trial involves 2 different treatments. Telatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

telatinib + Keytruda
ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly from the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years for reporting.

Closest Location

The Angeles Clinic and Research Institute - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 2 prior treatments for Carcinoma, Hepatocellular or one of the other 3 conditions listed above. There are 9 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Histologically confirmed gastric/esophagealgastric adenocarcinoma, recurrent, locally advanced or metastatic, PD-L1-positive disease (CPS ≥1), progressed on at least two prior lines of therapy, and/or discontinued second line therapy for intolerance, is indicated for Keytruda therapy. show original
Subjects must have one or more measurable metastatic lesions that have not been treated with radiation show original
If you have had radiation therapy in the past, you must wait 28 days before starting treatment in this study. show original
The person must be at least 18 years old. show original
The Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2 is a measure of how well a person is doing after treatment for cancer. show original
Adequate bone marrow, liver, and renal function
If you are of childbearing potential and you have a negative urine or serum pregnancy test, you are not pregnant. show original
Any woman or man who could potentially have a child must use birth control before participating in the study, for the entire time they are in the study, and for four months after the study is completed. show original
Can swallow tablets. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can carcinoma, hepatocellular be cured?

Add answer

There is no experimental evidence to support the belief that hepatocellular carcinoma can be cured. When cured, the patient has an increased risk of developing liver cancer. Because the risk is more pronounced in younger patients with cirrhosis or HBV-infection, this disease should be carefully evaluated and treated to reduce the risk of developing liver cancer after cure.

Unverified Answer

What is carcinoma, hepatocellular?

Add answer

The most common form of [liver cancer](https://www.withpower.com/clinical-trials/liver-cancer) – hepatocellular carcinoma (HCC) – is one of the leading causes of cancer-related deaths in China. The 5-year survival rate is 38% in China. The major risk factors for HCC in China include cirrhosis, hepatitis B infection, aflatoxin B1 contamination and alcohol consumption. Treatment of HCC largely depends on the stage of the disease. Surgery alone is generally recommended in patients at early stages and those in good condition; radiotherapy or chemotherapy is normally recommended for patients with advanced HCC, those at the late stages, or those who have recently undergone surgery and are unwell. Prognosis depends on the stage of HCC.

Unverified Answer

What causes carcinoma, hepatocellular?

Add answer

The most common site of hepatocarcinoma is the cirrhotic liver. More than 90% of HCCs are metastasized when they are discovered, and about 50% of the patients present with liver cirrhosis. Cirrhosis, hepatitis B and a long delay from HBV infection determine the development of HCC. Atypical morphology, hepatitis B surface antigen negativity. and hepatitis C virus infection increase the risk of HCC.

Unverified Answer

How many people get carcinoma, hepatocellular a year in the United States?

Add answer

There is the potential to prevent ∼300,000 new cases of carcinoma, hepatocellular in women and men annually in the US. However, there remains no clear evidence that any current screening strategy is effective except for an annual pap smear for women and men over age 70 years.

Unverified Answer

What are common treatments for carcinoma, hepatocellular?

Add answer

A combination of chemotherapy regimen for the treatment of HCC is a good option. The treatment of HCC does not include curative treatments; however, it can improve the quality of life and the patients' physical condition.

Unverified Answer

What are the signs of carcinoma, hepatocellular?

Add answer

The signs in liver function are similar both for HCC and for HCV. Hepatocellular carcinoma should be suspected in the presence of the following (in order of importance): alpha-fetoprotein >100 ng/ml or AFP/Albumin >50% ratio, tumor size >5 cm or BCL10 expression, hepatic venous outflow obstruction, and in patients with low BMI and cirrhosis, unexplained weight loss and anemia. HCC should be suspected by the presence of nodular lesions or masses.

Unverified Answer

Have there been other clinical trials involving telatinib?

Add answer

There may be additional benefit to the use of telatinib for patients with progressive advanced HCCs due to the potential for significant reduction in disease progression-related deaths.

Unverified Answer

Has telatinib proven to be more effective than a placebo?

Add answer

Telatinib may delay hepatocellular carcinoma progression after hepatic resection. Because of the slow absorption rate, it was more cost-effective to use telatinib for a longer period after surgery than to take the drug more frequently. Future studies are still necessary to determine the optimal dosing and duration of therapy.

Unverified Answer

What is telatinib?

Add answer

Telatinib is a small molecule kinase inhibitor and Bcr-a-kit tyrosine kinase inhibitor (ATKI) which has been developed to treat acute myelogenous leukaemias (AML)-related disease such as blast crisis, and chronic myelogenous leukaemia. Currently, there are numerous clinical trials (Phase II and IIIa) to examine the efficacy, safety and tolerability of telatinib in adult patients with AML. Some patients may show resistance to current treatments from the use or misuse of drugs.

Unverified Answer

Who should consider clinical trials for carcinoma, hepatocellular?

Add answer

We found no evidence that patients with carcinoma, hepatocellular, should be considered for clinical trials, as current therapeutic strategies are insufficient to prevent progression of the disease, although we observed a statistically significant probability of disease control. A prospective controlled trial to verify our findings is warranted.

Unverified Answer

Does carcinoma, hepatocellular run in families?

Add answer

Hepatocellular carcinoma is not a heritable disease. A family history of HCC is significantly linked to male sex, older age and hepatitis B virus infection, which are all risk factors of HCC. Data from a recent study suggest HCC is not a heritable disease.

Unverified Answer

Have there been any new discoveries for treating carcinoma, hepatocellular?

Add answer

The most effective anti-carcinogenic therapy was found to be a combination of p53 monoclonal antibody, bacillus Calmette-Guérin, and alkylating agents. The efficacy of these therapies in the treatment of HCC remains to be determined.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Hepatocellular by sharing your contact details with the study coordinator.